Antimicrobial susceptibility and clinical outcomes of tosufloxacin for mycoplasma pneumoniae among Japanese children in 2024
Author:
Open Access
- 1 September 2026
- journal article
- Published by SAGE Publications in Sage Open Medicine
- Vol. 14
Abstract
Background: Mycoplasma pneumoniae is a pathogen that causes community-acquired pneumonia. In 2024, for the first time since 2016, M. pneumoniae infections were epidemic in Japan. Recently, macrolide resistance has emerged among these pathogens. As tosufloxacin (TFLX) is the only antibiotic approved for use in children below the age of 8 years, this study investigated susceptibility and related clinical outcomes of TFLX treatment. Methods: This multi-center retrospective observational study evaluated 38 children with M. pneumoniae infections. Isolates were collected via nasopharyngeal culture, and TFLX minimum inhibitory concentrations (MICs) were determined. Detailed clinical courses were evaluated for patients treated with TFLX. Results: The TFLX minimum inhibitory concentration of their isolates ranged from 0.0625 to 0.5 g/mL, that TFLX MIC values remained within a low and favorable range Among seven patients who received TFLX against M. pneumoniae infections, five exhibited defervescence within 48 h of TFLX treatment onset, one was accompanied by COVID-19 infections, and one initiated TFLX on day 10 post-fever onset. Conclusion: In conclusion, TFLX is currently retains favorable microbiological susceptibility and suggested clinical usefulness.Keywords
This publication has 7 references indexed in Scilit:
- Novel Knowledge of Macrolide Resistance in Mycoplasma pneumoniae by Azithromycin ExposureMicroorganisms, 2024
- Periodic Genotype Shifts in Clinically Prevalent Mycoplasma pneumoniae Strains in JapanFrontiers in Cellular and Infection Microbiology, 2020
- Recent trends in practice patterns and impact of corticosteroid use on pediatric Mycoplasma pneumoniae-related respiratory infectionsRespiratory Investigation, 2018
- Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008–2015Emerging Infectious Diseases, 2017
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. ChildrenNew England Journal of Medicine, 2015
- In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and UreaplasmasAntimicrobial Agents and Chemotherapy, 2003
- Characteristics of Macrolide‐Resistant Mycoplasma pneumoniae Strains Isolated from Patients and Induced with Erythromycin In VitroMicrobiology and Immunology, 2001